Literature DB >> 2230272

Pilot trial of selective decontamination for prevention of bacterial infection in an intensive care unit.

J Flaherty1, C Nathan, S A Kabins, R A Weinstein.   

Abstract

Selective decontamination of the oropharynx and gastrointestinal tract with nonabsorbable antimicrobials and sucralfate, a stress ulcer prophylactic that maintains the normal gastric acid bacterial barrier, were compared for prevention of pneumonia in a cardiac surgery intensive care unit. Over 8 months, 51 patients received selective decontamination and 56 received sucralfate. The selective decontamination regimen included polymyxin, gentamicin, and nystatin given as an oral paste and as a solution; patients also received standard antacid or histamine2 blocker stress ulcer prophylaxis. Patients in the selective decontamination group had significantly less colonization of the oropharynx and stomach by gram-negative bacilli (12% vs. 55%, P less than .001), significantly fewer infections due to gram-negative bacilli (6% vs. 20%, P = .02), and fewer infections overall (12% vs. 27%, P = .04). There was one episode of pneumonia in the selective decontamination group and five in the sucralfate group. Mortality and length of stay did not differ between the groups, but those receiving selective decontamination had less than one-third as many days of systemic antibiotic therapy with no increase in colonization or infection with resistant gram-negative bacilli. Thus, selective decontamination appeared to reduce both extrapulmonary and pulmonary infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230272     DOI: 10.1093/infdis/162.6.1393

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Selective decontamination of the digestive tract: to stimulate or stifle?

Authors:  Marc J M Bonten; Christian Brun-Buisson; Robert A Weinstein
Journal:  Intensive Care Med       Date:  2003-05       Impact factor: 17.440

Review 2.  Selective decontamination of the digestive tract in intensive care.

Authors:  S J Boom; G Ramsay
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

Review 3.  Nosocomial pneumonia in the intensive care unit: mechanisms and significance.

Authors:  C A'Court; C S Garrard
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

4.  Comment on "risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination" by Leone et al.

Authors:  Mark A Fox; Richard E Sarginson; Durk F Zandstra; Iwan Meynaar; Hendrik K van Saene
Journal:  Intensive Care Med       Date:  2005-04-19       Impact factor: 17.440

Review 5.  Selective digestive decontamination in intensive care unit patients.

Authors: 
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 6.  Prevention of pneumonia by selective decontamination of the digestive tract (SDD).

Authors:  C P Stoutenbeek; H K van Saene
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

7.  Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials.

Authors:  R D'Amico; S Pifferi; C Leonetti; V Torri; A Tinazzi; A Liberati
Journal:  BMJ       Date:  1998-04-25

Review 8.  The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome.

Authors:  G A Nieuwenhuijzen; E A Deitch; R J Goris
Journal:  J Anat       Date:  1996-12       Impact factor: 2.610

Review 9.  Critical care pharmacotherapy. A review.

Authors:  M Tryba; P J Kulka
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

10.  Epidemiological impact of prolonged systematic use of topical SDD on bacterial colonization of the tracheobronchial tree and antibiotic resistance. A three year study.

Authors:  G Nardi; U Valentinis; A Proietti; A De Monte; A Di Silvestre; R Muzzi; R Peressutti; M G Troncon; F Giordano
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.